A single industry quietly underpins nearly every clinical decision made in a hospital today. When a cardiologist reviews a patient’s scan, adjusts a pacemaker wirelessly, or guides a catheter through a vessel no wider than a drinking straw, the precision behind that moment is the product of decades of engineering, regulatory science, and capital investment from the world’s top medical device companies.
In 2026, that industry is not slowing down. The global medical devices market, valued at approximately $678.88 billion in 2025 by Precedence Research, is now projected to cross $719 billion in 2026 and expand toward $1.2 trillion by 2035; a trajectory fueled by aging populations, chronic disease burdens, and a technological revolution that is integrating artificial intelligence into diagnostics and surgery at a pace few anticipated even five years ago.
The competitive dynamics within this sector have also shifted meaningfully. Mergers and strategic divestitures have reshuffled the rankings at the top. Companies that once dominated through sheer scale are now competing on innovation velocity, measured in cleared AI algorithms, approved robotic platforms, and next-generation continuous monitoring systems. The biggest medical device companies are no longer defined only by revenue; they are defined by their ability to translate R&D investment into clinical adoption at a global scale.
North America continues to hold the largest regional share at approximately 40% of global revenue, while Asia-Pacific is the fastest-growing region, driven by healthcare infrastructure investment in China, India, and Southeast Asia.
What follows is a thoroughly researched ranking of the top 10 medical device companies in 2026, based on reported and projected medical device segment revenues. Each entry examines what drove recent performance, what products are reshaping the company’s trajectory, and what strategic bets define its next chapter. This is where the industry stands today and where it is headed.
Top 10 Medical Device Companies 2026
1. Medtronic: Disciplined Focus at the Top
Medtronic retains its position as the world’s largest medical device company by revenue, though its hold on the summit is under genuine pressure heading into fiscal 2026. The Dublin-headquartered company reported fiscal year 2025 total revenue of approximately $33.5 billion across its medical device segments, with its cardiovascular portfolio emerging as the standout growth engine.
In Q2 of fiscal 2026, Medtronic’s cardiovascular segment grew 9.3% organically, driven by its Affera and PulseSelect pulsed-field ablation (PFA) systems for atrial fibrillation treatment, alongside strong results in Cardiac Rhythm and Heart Failure management.
The company’s neuromodulation franchise also accelerated, with BrainSense adaptive deep brain stimulation (aDBS) technology gaining clinical momentum. Medtronic is actively raising its fiscal 2026 organic revenue growth guidance to approximately 5.5%, with adjusted EPS guidance of $5.62 to $5.66. CEO Geoff Martha has described the company as accelerating toward higher and more profitable growth, a message backed by consecutive quarters of performance above guidance midpoints.
The most consequential strategic move is the planned separation of the Medtronic Diabetes business (which generated $2.8 billion in fiscal 2025 revenue) into an independent publicly traded company called MiniMed. The separation could, according to analysts and the Medtech Big 100 report, result in Medtronic ceding its number-one ranking to Johnson & Johnson MedTech by the time the next annual rankings are published. Whether that happens or not, the underlying business is structurally stronger, more focused, and growing faster than at any point in recent memory.
Key Highlights:
- FDA-cleared Affera and PulseSelect PFA systems driving double-digit cardiovascular growth
- BrainSense aDBS system expanding in high-growth neuromodulation segment
- Planned MiniMed diabetes spinoff aimed at sharpening strategic focus
- Organic revenue growth guidance raised to approximately 5.5% for FY2026
2. Johnson & Johnson MedTech: Competing to Lead
Johnson & Johnson MedTech, with approximately $31.9 billion in medical device revenue, is mounting the most credible challenge to Medtronic’s top position in years. Its six core business areas, oncology, immunology, neuroscience, cardiovascular, surgery, and vision, are each seeing meaningful innovation momentum.
The company’s Dualto energy system, which combines multiple energy modalities into a single integrated platform compatible with open and minimally invasive surgical settings, represents the kind of cross-platform versatility that defines competitive differentiation in surgical devices.
The Ottava soft-tissue surgical robotics platform remains one of the most anticipated product introductions in the industry. J&J MedTech announced in July 2025 that it plans to submit Ottava to the FDA for clearance in 2026. If approved, Ottava would position J&J as a direct competitor to Intuitive Surgical’s da Vinci ecosystem — a segment that has historically been Intuitive’s near-exclusive domain. Separately, J&J has joined forces with Nvidia and Amazon Web Services to launch the Polyphonic AI Fund for Surgery, underscoring its commitment to building AI-driven surgical intelligence at scale.
The company’s cardiovascular portfolio faced a setback when it paused sales of its Varipulse pulsed-field ablation system to investigate neurovascular events. The issue was subsequently resolved with an FDA-approved update to the system’s irrigation flow rate settings. The recovery from that pause and the broader expansion of J&J’s interventional cardiovascular portfolio will be closely watched through 2026.
Key Highlights:
- Ottava surgical robot FDA submission planned for 2026, targeting Intuitive’s market
- Polyphonic AI Fund for Surgery launched in partnership with Nvidia and AWS
- Dualto integrated energy platform now commercially available
- Recovery of Varipulse PFA system following FDA-cleared technical update
3. Abbott Laboratories: From Diagnostics to Mass-Market Monitoring
Abbott’s climb to third in global medtech rankings — up from its prior position — reflects a sustained and deliberate strategy of broadening its addressable market. Its medical device segment generated approximately $28.3 billion in 2025 revenue, with the FreeStyle Libre continuous glucose monitoring (CGM) platform continuing to be one of the fastest-growing franchises in the entire medical technology industry. Libre’s growth has been driven not only by its clinical population of diabetics but by FDA clearances for over-the-counter CGM systems — the Lingo and Libre Rio — that bring glucose monitoring to health-conscious consumers who have never carried a diabetes diagnosis.
Abbott’s cardiology portfolio is equally impressive. The Aveir DR dual-chamber leadless pacemaker system and the Volt pulsed-field ablation system represent the company’s ambition to own multiple segments of the structural heart and electrophysiology space simultaneously. On the diagnostics side, Abbott’s point-of-care and molecular diagnostics platforms continue to support health systems globally with rapid, accurate testing infrastructure.
The broader significance of Abbott’s rise is what it signals about where medical device growth is heading. Traditional device categories like orthopedic implants and surgical instruments remain large, but the highest growth rates are concentrated in chronic disease management, wearables, and connected diagnostics. Abbott has positioned itself at the center of that transition more successfully than almost any other company at its scale.
Key Highlights:
- FreeStyle Libre CGM remains one of the fastest-growing platforms in global medtech
- FDA-cleared Lingo and Libre Rio OTC CGM systems expanding the addressable market
- Aveir DR dual-chamber leadless pacemaker commercially available
- Volt PFA system in advanced development for electrophysiology market
4. Siemens Healthineers: Precision Imaging at Scale
Siemens Healthineers generated approximately $25.7 billion in revenue in 2025, maintaining its leadership in diagnostic imaging with a global market share of approximately 23% in that segment. The company’s Magnetom Cima.X 3T MRI system — cleared by the FDA — sets a new benchmark for imaging precision in neurological and musculoskeletal applications. Its Mammomat B.brilliant mammography system received FDA Premarket Approval in September 2024 for its 3D imaging capability, extending Siemens’ reach in breast cancer screening.
The company’s Syngo Virtual Cockpit technology, which enables real-time remote scanning collaboration between technologists and radiologists across physical distances, has particular relevance in markets where imaging specialist shortages create workflow bottlenecks. In September 2024, Siemens also expanded its European footprint in PET radiopharmaceuticals by acquiring a diagnostics division from Novartis.
Currency headwinds have modestly weighed on Siemens Healthineers’ USD-reported revenues — the company experienced a slight year-on-year revenue decline in dollar terms in 2024 despite underlying growth in euros. Its guidance for 2024 called for 4.5% to 6.5% sales growth, and the underlying demand environment for premium imaging remains robust as healthcare systems in both mature and emerging markets invest in next-generation diagnostic infrastructure.
Key Highlights:
- Magnetom Cima.X 3T MRI system enhancing neurological imaging precision
- FDA Premarket Approval for 3D capability on Mammomat B.brilliant mammography system
- Syngo Virtual Cockpit enabling remote imaging collaboration across sites
- Acquisition of Novartis diagnostics division strengthening European PET position
5. Medline Industries: The Private Giant That Rarely Gets Headlines
Medline Industries, with approximately $25.2 billion in revenue, is the largest private company on this list — and one of the most frequently underestimated forces in global healthcare supply. Operating across more than 100 countries, Medline provides medical supplies, surgical solutions, and clinical products that hospitals, ambulatory surgery centers, and long-term care facilities depend on daily. Its $950 million acquisition of Ecolab’s surgical solutions business expanded its operating room portfolio significantly, adding sterile drape systems, fluid management products, and procedural kits.
Unlike the companies above it in the rankings, Medline’s growth story is less about breakthrough device innovation and more about supply chain resilience, vertical integration, and the ability to serve healthcare systems at scale. The company expanded its product testing laboratory in Mundelein, Illinois, and has continued building direct relationships with health systems that are seeking to reduce dependence on distribution intermediaries. As supply chain disruption remains a persistent concern in healthcare, Medline’s model continues to attract institutional trust.
Key Highlights:
- $950M acquisition of Ecolab’s surgical solutions strengthens OR portfolio
- Operations in over 100 countries with growing direct health system relationships
- Expanded product testing lab capabilities at Mundelein, Illinois
- Strategic positioning as a supply chain resilience partner for health systems
6. Stryker: Robotics, Acquisitions, and a Market Handed to It
Stryker’s 2025 revenue of approximately $22.6 billion reflects a 10.24% increase over the prior year — one of the strongest growth rates among large-cap medical device companies. The Mako robotic arm system continues to be the company’s most visible growth catalyst, with new clinical applications in shoulder and spine surgery expanding its reach well beyond its original knee arthroplasty roots. Stryker’s acquisition of Vertos Medical in October 2024 brought minimally invasive lumbar decompression technology into the portfolio, adding a high-growth interventional pain management segment.
Perhaps the most unexpected tailwind for Stryker was a competitor’s exit. When Globus Medical — itself a formidable spine player following its merger with NuVasive — prompted Stryker to reassess the competitive landscape, the net effect has been a re-energized Stryker spine franchise. The company’s neurotechnology segment, along with its emergency medical services equipment business, provides revenue diversification that most pure-play device companies lack. Its myMako app, designed for surgical planning using Apple Vision Pro spatial computing, reflects Stryker’s intent to integrate mixed-reality tools into the procedural workflow.
Key Highlights:
- Mako robotic system expanding into shoulder and spine surgical applications
- Acquisition of Vertos Medical adding interventional pain management capability
- 10.24% revenue growth in fiscal 2025 — among the highest of top 10 peers
- myMako app for Apple Vision Pro integrating spatial computing into surgical planning
7. Becton Dickinson: Restructuring Into Focus
Becton Dickinson, known in the industry as BD, generated approximately $21.7 billion in medical device and supply revenue in fiscal year 2025. The company has been operating through a sustained strategic review aimed at sharpening its portfolio around core competencies in medication management, medication delivery, diagnostics, and surgery. Its quarterly revenues have shown consistent growth — fiscal Q3 2025 revenues reached $5.89 billion, up 8.3% year over year.
BD’s separation of its biosciences and diagnostic solutions segment into an independent publicly traded company was a significant 2024 announcement, with the transaction expected to further sharpen its medtech identity heading into 2026. The remaining BD business is increasingly defined by its BD Alaris infusion systems, vascular access devices, and medication management platforms — all categories with strong installed-base dynamics and recurring revenue characteristics. The company is also investing in molecular diagnostics and advancing automation in lab workflows, particularly for clinical microbiology.
Key Highlights:
- Planned biosciences and diagnostics spinoff sharpening core medtech focus
- BD Alaris infusion system generating strong recurring revenue across hospitals
- Q3 FY2025 revenue of $5.89 billion, up 8.3% year over year
- Vascular access and medication management platforms anchoring core portfolio
8. GE HealthCare: AI at the Core of Every System
GE HealthCare, operating independently since its separation from General Electric in early 2023, reported approximately $19.7 billion in revenue in 2025. The company has invested substantially in AI-enabled diagnostic systems, with its Voluson Signature ultrasound line and AI-enhanced imaging platforms positioned as the next frontier in precision diagnostics. Its acquisition of Intelligent Ultrasound’s AI software business and earlier deals such as Caption Health reflect a clear strategic conviction: that AI-augmented imaging will become the standard of care, not a premium add-on.
The company’s Revolution RT oncology solutions are gaining traction in radiation therapy planning, where AI-assisted contouring and dose optimization reduce treatment planning time. GE HealthCare has also been investing in its life sciences segment, which provides bioprocessing equipment for pharmaceutical manufacturers — a less visible but strategically important revenue stream. Currency exposure and regional market softness in China have created headwinds, but the underlying AI diagnostics thesis continues to attract both institutional customers and investor confidence.
Key Highlights:
- Voluson Signature ultrasound systems incorporating AI-driven diagnostic intelligence
- Acquisition of Intelligent Ultrasound’s AI software advancing algorithm library
- Revolution RT oncology platform addressing radiation therapy planning efficiency
- Partnerships with Volta Medical expanding cardiac AI applications
9. Boston Scientific: The Fastest Climber in the Top 10
Boston Scientific deserves particular attention in any analysis of the best medical device companies in 2026 because it is growing faster than almost any other company in the top ten. Full-year 2025 net sales grew approximately 18 to 19% on a reported basis, with organic growth of 14 to 15% — figures that no other large-cap medtech company matched. The primary driver is the FARAPULSE Pulsed Field Ablation system, which received expanded FDA approval in 2025 to treat drug-refractory symptomatic persistent atrial fibrillation. In Q2 2025, cardiovascular segment revenue grew 26.8% year over year on a reported basis.
Boston Scientific is also advancing rapidly in minimally invasive surgery, urology, and endoscopy. The company received European marketing authorization for its Lotus Edge TAVR system for transcatheter aortic valve replacement, expanding its structural heart portfolio in European markets.
With a strategy centered on high-growth interventional procedures and a disciplined M&A track record, Boston Scientific is widely expected to move further up the rankings among the leading medical device companies as fiscal 2026 results are published.
Key Highlights:
- FARAPULSE PFA system driving cardiovascular growth above 25% in key quarters
- 18-19% full-year 2025 revenue growth — fastest among the largest medtech companies
- Lotus Edge TAVR system receiving EU marketing authorization
- Cardiovascular, urology, and endoscopy segments all contributing to organic momentum
10. Intuitive Surgical: The Robotic Standard Bearer
Intuitive Surgical rounds out the top 10 with approximately $9.7 billion in 2025 revenue — a number that understates its strategic importance to the industry. The company is the de facto global standard for robotic-assisted surgery, with its da Vinci surgical system installed base growing to 10,763 systems as of Q3 2025, up 13% year over year. Worldwide procedures across da Vinci and Ion platforms grew approximately 20% in Q3 2025, with da Vinci procedures up 19% and Ion lung navigation procedures up 52%.
The commercial ramp of the da Vinci 5 — the fifth generation of the flagship system — is accelerating meaningfully, with 240 da Vinci 5 placements in Q3 2025 alone compared to 110 in the same quarter of 2024. Q3 2025 revenue of $2.51 billion represented 23% growth year over year. Intuitive’s recurring revenue model, which generates substantial instrument and accessory revenue from each installed system, creates a financial flywheel that few medical device business models can replicate.
Key Highlights:
- Da Vinci 5 system placements accelerating with 240 units placed in Q3 2025
- Worldwide robotic procedure volume up approximately 20% year over year
- Ion lung navigation system procedures growing 52% in the most recent quarter
- Installed base of 10,763 surgical systems generating durable recurring revenue
Top 10 Medical Device Companies Rankings
| Rank | Company | FY2025 Revenue (est.) | Key Focus Areas | Headquarters |
|---|---|---|---|---|
| 1 | Medtronic | ~$33.5B | Orthopedics, surgical robotics, and neurotechnology | Dublin, Ireland |
| 2 | Johnson & Johnson MedTech | ~$31.9B | Orthopedics, surgical robotics, cardiovascular | New Brunswick, NJ, USA |
| 3 | Abbott Laboratories | ~$28.3B | Diabetes care, cardiology, diagnostics | Abbott Park, IL, USA |
| 4 | Siemens Healthineers | ~$25.7B | Diagnostic imaging, in vitro diagnostics, oncology | Erlangen, Germany |
| 5 | Medline Industries | ~$25.2B | Medical supplies, surgical solutions | Northfield, IL, USA |
| 6 | Stryker | ~$22.6B | Medication management, diagnostics, and surgery | Kalamazoo, MI, USA |
| 7 | Becton Dickinson | ~$21.7B | Medication management, diagnostics, surgery | Franklin Lakes, NJ, USA |
| 8 | GE HealthCare | ~$19.7B | Diagnostic imaging, AI-driven diagnostics | Boston, MA, USA |
| 9 | Boston Scientific | ~$18.5B | Cardiology, urology, endoscopy | Marlborough, MA, USA |
| 10 | Intuitive Surgical | ~$9.7B | Robotic-assisted surgery | Sunnyvale, CA, USA |
Sources: Company annual reports, SEC filings, Capital IQ, Medical Design & Outsourcing Medtech Big 100 (2025 edition). Revenue figures reflect medical device segments only and are subject to currency adjustments for non-USD reporters.
What Is Driving Growth Across the Sector
Artificial Intelligence Is No Longer a Differentiator: It Is a Requirement
Five years ago, an AI feature on a medical device was a marketing point. In 2026, it is a baseline expectation in imaging, diagnostics, and surgical guidance. GE HealthCare, Siemens Healthineers, and Abbott are each embedding AI into platforms that are already deployed across thousands of clinical sites.
The FDA’s cleared AI/ML-based software as a medical device (SaMD) catalog has grown dramatically, and the regulatory pathway is maturing. Companies that cannot demonstrate AI-enabled clinical value improvement are losing procurement conversations to those that can.
Surgical Robotics Is Expanding Its Addressable Market
The robotic surgery market is no longer a niche segment dominated by a single company. Intuitive Surgical remains the leader, but Medtronic’s Hugo system, Stryker’s Mako, and J&J’s anticipated Ottava are each targeting procedure categories where robotic assistance has historically been absent.
The broader impact is that robotic surgery is moving from tertiary academic medical centers into community hospitals and ambulatory surgery centers — a transition that multiplies the addressable patient population substantially.
Pulsed Field Ablation Is Reshaping Electrophysiology
One of the most consequential technology shifts in 2025 and into 2026 is the widespread clinical adoption of pulsed field ablation for atrial fibrillation treatment. PFA selectively ablates cardiac tissue with minimal collateral damage to adjacent structures; a significant clinical improvement over radiofrequency and cryoablation technologies.
Medtronic’s Affera and PulseSelect, Boston Scientific’s FARAPULSE, and Abbott’s Volt are all competing in this category, creating one of the most active competitive battles in modern cardtech.
Chronic Disease Management Is Generating Recurring Revenue at Scale
Abbott’s FreeStyle Libre franchise is the most visible example of a broader trend: medical devices designed for chronic disease management generate recurring revenue through consumable sensors, software subscriptions, and data services.
This business model is more predictable, more defensible against competitive disruption, and more valuable to investors than traditional capital equipment models. Diabetes care, continuous cardiac monitoring, and remote patient monitoring are all expanding under this dynamic.
Regulatory and Market Challenges
The leading medical device companies do not operate in a frictionless environment. Regulatory scrutiny from the FDA and European Medicines Agency (EMA) has intensified, with post-market surveillance obligations increasing under the EU’s Medical Device Regulation.
Cybersecurity documentation is now a mandatory component of device clearance submissions in the US, reflecting the reality that connected medical devices are potential targets for cyber threats. Companies with legacy device portfolios face the most acute compliance exposure.
Regional dynamics add further complexity. China, once a reliable growth market for imaging and diagnostics, has seen softer-than-expected demand from hospital procurement slowdowns.
GE HealthCare and Siemens Healthineers have each cited China headwinds in recent reporting periods. Currency volatility also affects the USD-translated revenues of European companies, creating apparent revenue declines that mask underlying business strength.
The Road Ahead for the Biggest Medical Device Companies
The medtech industry in 2026 is characterized by a productive tension between scale and speed. The largest medical device companies have the capital, the installed bases, and the regulatory relationships to commercialize innovation on a global scale.
But they also face the organizational inertia that comes with size, while nimbler competitors like Boston Scientific and Intuitive Surgical demonstrate that focused strategies can generate growth rates that dwarf the broader sector average.
The convergence of AI, robotics, connected diagnostics, and personalized care is not a future scenario — it is already the present reality shaping procurement decisions across health systems worldwide.
The companies that understand how to integrate these technologies into clinical workflows, demonstrate clear patient outcomes data, and build durable, recurring revenue relationships will define the rankings not just in 2026 but well into the next decade. The global medical devices market is on its way to $1.2 trillion by 2035, and the companies profiled here are positioned to capture a disproportionate share of that growth.
Frequently Asked Questions
1. Which is the largest medical device company in 2026?
Medtronic remains the largest medical device company by revenue heading into 2026, with approximately $33.5 billion in medical device segment revenue for fiscal year 2025. However, the planned spinoff of its MiniMed diabetes business could shift the top ranking to Johnson & Johnson MedTech, which is growing rapidly and is expected to close the revenue gap within the near term.
2. What are the top 10 medical device companies in 2026?
Based on medical device segment revenues, the top 10 are Medtronic, Johnson & Johnson MedTech, Abbott Laboratories, Siemens Healthineers, Medline Industries, Stryker, Becton Dickinson, GE HealthCare, Boston Scientific, and Intuitive Surgical. Rankings are based on FY2025 reported or estimated revenue figures from the company’s SEC filings and industry reports.
3. How big is the global medical device market in 2026?
The global medical devices market is valued at approximately $604 to $719 billion in 2026, depending on the methodology and scope used by research firms. According to Precedence Research and Fortune Business Insights, the market is projected to reach between $955 billion and $1.2 trillion by 2034 to 2035, growing at a compound annual growth rate of approximately 6% to 7%.
4. What role does AI play in medical devices today?
Artificial intelligence is now integrated into diagnostic imaging, surgical robotics, continuous monitoring systems, and clinical decision support tools. Companies like GE HealthCare, Siemens Healthineers, and Abbott are deploying AI-enabled platforms across radiology, ultrasound, and glucose monitoring. The FDA has cleared hundreds of AI-enabled medical devices, and AI is increasingly treated as a baseline product requirement rather than a premium feature.
5. Why is Boston Scientific growing so fast?
Boston Scientific has grown at an exceptionally high rate — approximately 18 to 19% in reported revenue for 2025 — primarily due to its FARAPULSE pulsed-field ablation system for atrial fibrillation, which gained significant FDA clearance expansions. Its cardiovascular segment grew over 25% in certain quarters, and its diversified portfolio across urology, endoscopy, and minimally invasive surgery contributed to broad-based momentum.
6. What is pulsed field ablation, and why does it matter?
Pulsed field ablation (PFA) is a cardiac ablation technology that uses electrical pulses to selectively destroy targeted heart tissue with minimal impact on surrounding structures. It is considered a safer and more precise approach to treating atrial fibrillation compared to older thermal methods like radiofrequency ablation. Companies including Boston Scientific, Medtronic, and Abbott are competing aggressively in this space, making it one of the most active technology battlegrounds in medical devices today.
7. Which medical device company leads in surgical robotics?
Intuitive Surgical remains the global leader in robotic-assisted surgery, with an installed base of over 10,700 da Vinci systems and rapidly growing procedure volumes. However, Stryker’s Mako system dominates orthopedic robotics, and Johnson & Johnson is preparing the Ottava platform for FDA submission in 2026. Medtronic’s Hugo system is also gaining traction internationally, making surgical robotics one of the most competitive segments in the industry.
8. How do medical device companies in the US compare to European ones?
US-based companies dominate the global top 10 by revenue, reflecting the size of the American healthcare market, favorable reimbursement dynamics, and proximity to the FDA — the world’s most influential device regulator. European companies like Siemens Healthineers benefit from strong positions in diagnostic imaging and laboratory diagnostics. The EU’s Medical Device Regulation has increased compliance complexity for all companies selling into Europe, creating higher barriers to entry that tend to benefit established players.
9. What is Medtronic’s MiniMed spinoff, and what does it mean for rankings?
MiniMed is the name of the independent company Medtronic plans to create by separating its diabetes business, which generated approximately $2.8 billion in fiscal 2025 revenue. Once separated, Medtronic’s total revenue base will shrink accordingly, potentially allowing Johnson & Johnson MedTech to surpass it in the next annual rankings. The spinoff is framed as a strategic sharpening move — allowing both entities to focus their capital allocation and R&D investment on their respective core markets.
10. What are the biggest trends shaping medical devices in 2026?
The most impactful trends include the mass-market expansion of continuous glucose monitoring, the accelerating clinical adoption of pulsed field ablation in electrophysiology, the scaling of robotic surgery into community hospitals, AI integration across imaging and diagnostics platforms, and the increasing importance of remote patient monitoring as a care delivery model. Regulatory complexity, particularly in the EU and around cybersecurity documentation, is also reshaping how companies approach product development timelines.